Cargando…

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial

INTRODUCTION: Sleep-wake and circadian disturbance is a key feature of mood disorders with a potential causal role and particular relevance to young people. Brexpiprazole is a second-generation antipsychotic medication with demonstrated efficacy as an adjunct to antidepressant treatment for major de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpenter, Joanne S, Zmicerevska, Natalia, Crouse, Jacob J, Nichles, Alissa, Garland, Alexandra, Song, Yun Ju Christine, Wilson, Chloe, Rohleder, Cathrin, McHugh, Catherine, Leweke, F. Markus, Koethe, Dagmar, Scott, Elizabeth M, Hickie, Ian B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454051/ https://www.ncbi.nlm.nih.gov/pubmed/36691133 http://dx.doi.org/10.1136/bmjopen-2021-056298

Ejemplares similares

Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep–wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol
por: Wilson, Chloe, et al.
Publicado: (2023)

Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services
por: Rohleder, Cathrin, et al.
Publicado: (2020)

Neurobiology Youth Follow-up Study: protocol to establish a longitudinal and prospective research database using multimodal assessments for current and past mental health treatment-seeking young people within an early intervention service
por: Nichles, Alissa, et al.
Publicado: (2021)

Effect of an online healthy lifestyle psychoeducation programme to improve cardiometabolic outcomes and affective symptoms in youth receiving mental health care: study protocol for a pilot clinical trial.
por: Wilson, Chloe, et al.
Publicado: (2021)

Premature mortality in early-intervention mental health services: a data linkage study protocol to examine mortality and morbidity outcomes in a cohort of help-seeking young people
por: McHugh, Catherine, et al.
Publicado: (2022)

EMPOWERED trial: protocol for a randomised control trial of digitally supported, highly personalised and measurement-based care to improve functional outcomes in young people with mood disorders
por: Hickie, Ian B, et al.
Publicado: (2023)

Cohort profile: the Brain and Mind Centre Optymise cohort: tracking multidimensional outcomes in young people presenting for mental healthcare
por: Carpenter, Joanne S, et al.
Publicado: (2020)

Delineating the trajectories of social and occupational functioning of young people attending early intervention mental health services in Australia: a longitudinal study
por: Iorfino, Frank, et al.
Publicado: (2018)

Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
por: Koethe, Dagmar, et al.
Publicado: (2023)

Predictive modelling of deliberate self-harm and suicide attempts in young people accessing primary care: a machine learning analysis of a longitudinal study
por: McHugh, Catherine M., et al.
Publicado: (2023)

Protocol for a young adult mental health (Uspace) cohort: personalising multidimensional care in young people admitted to hospital
por: Tickell, Ashleigh M, et al.
Publicado: (2021)

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
por: Leweke, F. Markus, et al.
Publicado: (2021)

Neural Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-Episode Psychosis, and Healthy Volunteers
por: Bien, Christian G., et al.
Publicado: (2021)

Clinical staging and the differential risks for clinical and functional outcomes in young people presenting for youth mental health care
por: Capon, William, et al.
Publicado: (2022)

Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and N-Acylethanolamines by Liquid Chromatography–Tandem Mass Spectrometry
por: Couttas, Timothy A., et al.
Publicado: (2023)

Predicting self-harm within six months after initial presentation to youth mental health services: A machine learning study
por: Iorfino, Frank, et al.
Publicado: (2020)

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
por: Woelfl, Timo, et al.
Publicado: (2020)

Exploring associations between early substance use and longitudinal socio-occupational functioning in young people engaged in a mental health service
por: Crouse, Jacob J., et al.
Publicado: (2019)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Modelling associations between neurocognition and functional course in young people with emerging mental disorders: a longitudinal cohort study
por: Crouse, Jacob J., et al.
Publicado: (2020)

Transdiagnostic neurocognitive subgroups and functional course in young people with emerging mental disorders: a cohort study
por: Crouse, Jacob J., et al.
Publicado: (2020)

Editorial: Immune Associated Mental Illnesses in Adolescents and Young Adults: Pathophysiological Role and Therapeutic Perspectives
por: Banati, Richard B., et al.
Publicado: (2022)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
por: Rohleder, Cathrin, et al.
Publicado: (2016)

Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review
por: Couttas, Timothy A., et al.
Publicado: (2022)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Premature mortality in young people accessing early intervention youth mental healthcare: data-linkage cohort study
por: McHugh, Catherine M., et al.
Publicado: (2023)

Case Report: Severe Adolescent Major Depressive Syndrome Turns Out to Be an Unusual Case of Anti-NMDA Receptor Encephalitis
por: Moldavski, Alexander, et al.
Publicado: (2021)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

What is the prevalence, and what are the clinical correlates, of insulin resistance in young people presenting for mental health care? A cross-sectional study
por: Scott, Elizabeth M, et al.
Publicado: (2019)

Manipulating the sleep-wake cycle and circadian rhythms to improve clinical management of major depression
por: Hickie, Ian B, et al.
Publicado: (2013)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive–compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study
por: Westwell-Roper, Clara, et al.
Publicado: (2022)

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
por: Yoon, Seoyoung, et al.
Publicado: (2016)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jf0n2ln2eh7clv78l9282nq5q2